Resolved: Targeting a Higher Hemoglobin is Associated with Greater Risk in Patients with CKD Anemia: Pro

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2009 Jul 7

PMID 19579295

Citations 4

Authors

Ajay K Singh

Affiliations

Soon will be listed here.

Abstract

Some time has passed since the torrent of discussion surrounding the cardiovascular risk of pushing up hemoglobin concentrations in dialysis patients with erythropoietin. The debate here reflects a look back on the tension produced by confusing data and outcomes. Is it the target hemoglobin per se or the high doses of erythropoietin in subsets of resistant patients that is the problem? You decide.

Citing Articles

Short versus long-acting erythropoiesis-stimulating agents for anemia management in Egyptian hemodialysis patients.

Soliman A, Magdy S, Ayoub H, Ebid A Qatar Med J. 2024; 2024(1):16.

PMID: 38567102 PMC: 10985414. DOI: 10.5339/qmj.2024.16.

Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19-A Single Center Experience.

Niculae A, Peride I, Nechita A, Petcu L, Tiglis M, Checherita I J Pers Med. 2022; 12(6).

PMID: 35743751 PMC: 9224649. DOI: 10.3390/jpm12060966.

Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).

Park H, Liu X, Henry L, Harman J, Ross E BMC Nephrol. 2018; 19(1):318.

PMID: 30413150 PMC: 6230235. DOI: 10.1186/s12882-018-1119-7.

Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.

Provatopoulou S, Ziroyiannis P Hippokratia. 2011; 15(2):109-15.

PMID: 22110290 PMC: 3208971.